Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA2 | P00918 | 3/20 | 0.30 |
| ▸ | CA7 | P43166 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 3/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934925 | 0.82 | TSHR (0.36) | TSHRADRA1APDE4DLMNA | |
| SCHEMBL16045520 | 0.79 | TSHR (0.46) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL16046615 | 0.79 | TSHR (0.46) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL278989 | 0.77 | TSHR (0.43) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL9746345 | 0.76 | TSHR (0.39) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL16046806 | 0.75 | TSHR (0.42) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL1089594 | 0.75 | CA2 (0.44) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL1242991 | 0.75 | TSHR (0.42) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL28510361 | 0.75 | TSHR (0.37) | TSHRADRA1APDE4DLMNAHCAR2 | |
| SCHEMBL7644750 | 0.74 | LMNA (0.44) | TSHRADRA1APDE4DLMNAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | TSHR 280/4885ADRA1A 81/4885PDE4D 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.